Menu

地舒单抗如何用?

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

How to use? Desosumab is indicated for the treatment of: Bone Metastases from Solid Tumors - Indicated for the prevention of bone-related events in patients with bone metastases from solid tumors. Important limitations of use: Not indicated for the prevention of bone-related events in patients with multiple myeloma.

Desosumab needs to be administered by injection, 120 mg subcutaneously in the upper arm, upper thigh, or abdomen, once every 4 weeks. Calcium and vitamin D are given when treatment or prevention of hypocalcemia is required.

Desosumab is available in 120 mg/1.7 mL (70 mg/mL) single-use vials. Refrigerate at 2-8°C (36-46°F); do not freeze. Must be used within 14 days after removal from the refrigerator, do not expose to temperatures above 25°C (77°F), and avoid direct light and heat.

Hypocalcemia must be corrected before denosumab therapy can be initiated. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.

Patients who are concurrently taking immunosuppressants or have compromised immune systems may be at increased risk of serious infections, and physicians need to fully consider the benefit-risk ratio before prescribing denosumab to such patients.

Allergic reactions may occur during use; if allergic reactions occur, use should be discontinued permanently. Denosumab may harm the fetus. Women of childbearing age should be informed of the dangers of the drug and take effective contraceptive measures. Its safety and effectiveness have not been established in pediatric patients and use in pediatric patients is not recommended. In order to avoid other adverse injuries during medication, patients should promptly and truthfully inform their doctors if they have other special circumstances, including the need to take other medications.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。